A New Oral GH Secretagogue With a Completely Different Chemical Structure From Existing Drugs
SM-130686, a novel oxindole-based oral GH secretagogue structurally distinct from MK-677 and GHRP, showed potent GH-releasing activity in vitro and in vivo with body weight and IGF-1 increases in rats.
Quick Facts
What This Study Found
SM-130686, a structurally novel oxindole GH secretagogue, showed potent in-vitro and in-vivo GH-releasing activity, increased IGF-1 and body weight in rats, and was orally active, demonstrating a new chemical class for GHS-R targeting.
Key Numbers
How They Did This
Preclinical pharmacology study. SM-130686 tested in rat pituitary cell assays (in vitro), acute GH release in rats and dogs (in vivo), and chronic dosing for body weight and IGF-1 effects.
Why This Research Matters
Having structurally diverse drugs for the same target provides backup options if one class has safety issues, and may reveal compounds with better selectivity or pharmacokinetics.
The Bigger Picture
Drug development benefits from chemical diversity. Multiple structural classes targeting the same receptor provide safety alternatives and opportunities for discovering compounds with superior drug properties.
What This Study Doesn't Tell Us
Preclinical data only. Selectivity profile not fully characterized. Long-term safety unknown. No human data.
Questions This Raises
- ?Does the novel scaffold provide advantages over MK-677?
- ?What is SM-130686's selectivity profile?
- ?Will it advance to human clinical trials?
Trust & Context
- Key Stat:
- New chemical class SM-130686's oxindole structure is completely different from MK-677, GHRP, or NN703 — yet it potently activates the same receptor
- Evidence Grade:
- Preliminary preclinical evidence with comprehensive in-vitro and in-vivo pharmacology demonstrating a new viable GH secretagogue chemical class.
- Study Age:
- Published in 2001. SM-130686 represented one of several novel chemical approaches being explored for GH secretagogue drug development.
- Original Title:
- Pharmacological profile of a new orally active growth hormone secretagogue, SM-130686.
- Published In:
- The Journal of endocrinology, 171(3), 481-9 (2001)
- Authors:
- Nagamine, J, Nagata, R, Seki, H, Nomura-Akimaru, N, Ueki, Y, Kumagai, K, Taiji, M, Noguchi, H
- Database ID:
- RPEP-00683
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Why develop a different type of GH secretagogue?
Having drugs with different chemical structures targeting the same receptor provides backup options. If one drug has side effects, a structurally different one might not. It also allows selection of the best drug properties.
How does this compare to MK-677?
SM-130686 targets the same receptor as MK-677 but has a completely different chemical structure. This means it may have different absorption, metabolism, and side effect profiles, potentially offering advantages for certain patients.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00683APA
Nagamine, J; Nagata, R; Seki, H; Nomura-Akimaru, N; Ueki, Y; Kumagai, K; Taiji, M; Noguchi, H. (2001). Pharmacological profile of a new orally active growth hormone secretagogue, SM-130686.. The Journal of endocrinology, 171(3), 481-9.
MLA
Nagamine, J, et al. "Pharmacological profile of a new orally active growth hormone secretagogue, SM-130686.." The Journal of endocrinology, 2001.
RethinkPeptides
RethinkPeptides Research Database. "Pharmacological profile of a new orally active growth hormon..." RPEP-00683. Retrieved from https://rethinkpeptides.com/research/nagamine-2001-pharmacological-profile-of-a
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.